AG
KNTE

Artal Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Artal Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-125,000
Closed -$379K – 124
2023
Q2 		$379K Hold
125,000
– – 0.01% 108
2023
Q1 		$781K Hold
125,000
– – 0.05% 95
2022
Q4 		$763K Hold
125,000
– – 0.04% 107
2022
Q3 		$1.49M Hold
125,000
– – 0.06% 100
2022
Q2 		$1.58M Hold
125,000
– – 0.08% 107
2022
Q1 		$1.41M Hold
125,000
– – 0.06% 117
2021
Q4 		$2.21M Hold
125,000
– – 0.06% 130
2021
Q3 		$2.88M Hold
125,000
– – 0.06% 127
2021
Q2 		$2.91M Hold
125,000
– – 0.06% 130
2021
Q1 		$3.9M Hold
125,000
– – 0.07% 128
2020
Q4 		$4.97M Buy
+125,000
New +$5.02M 0.11% 109

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Artal Group's KNTE Position: Q3 2023 in Review

Artal Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q3 2023, closing a stake of 125,000 shares — an estimated $379K sold.

Artal Group first reported a position in KNTE in Q4 2020 and held it in 11 quarters. The position peaked at $4.97M in Q4 2020. 58 funds tracked by Wall St. Rank hold KNTE as of Q3 2023.

  • Artal Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Artal Group sold 125,000 Kinnate Biopharma Inc. Common Stock shares in Q3 2023, an estimated $379K.
  • Artal Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 11 quarters.
  • Artal Group's Kinnate Biopharma Inc. Common Stock position peaked at $4.97M in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q3 2023.

Based on Artal Group's 13F filing for Q3 2023, filed 13 Nov 2023.